Creative Bioarray Established in Vitro and in Vivo Blood Brain Barrier Assay to Develop Drugs for Neurological Diseases.

Shirley, USA - June 15, 2021 /MarketersMedia/ —

Creative Bioarray, the innovative biotechnology company focuses on developing cutting-edge products and high quality services to support research in the field of pharmaceutical, biotechnology, agricultural, and diagnostics. Creative Bioarray develops flexible custom-designed experiments to support diverse needs and goals. Recently, Creative Bioarray announced the release of blood brain barrier assay to develop drugs in order to treat neurological diseases.

As an active interface between the circulation and the central nervous system (CNS), BBB strictly controls the molecular and cellular traffic between the blood and the brain, thus playing an important role in providing the homeostatic environment required for normal neuronal function. BBB protects brain nerve tissue from plasma composition fluctuations and pathogens, and maintains the steady state of brain parenchyma by restricting the non-specific flow of ions, peptides, proteins and even cells into and out of the brain. Many drugs developed to treat central nervous system diseases cannot reach the brain parenchyma at therapeutically relevant concentrations. Therefore, the BBB model is essential to characterize the BBB permeability of drug candidates as early as possible in the drug development pipeline.

With decades of experience in blood-brain barrier research and operation and technology platforms, in addition to primary cell isolation and culture technology, Creative Bioarray also uses primary brain endothelial cells to establish an in vitro blood-brain barrier model, and will perform in vitro blood-brain barrier assays, such as Oxygen glucose deprivation to simulate a stroke condition and the following items will be evaluated.

Creative Bioarray can utilize double and triple co-culture systems to generate in vitro BBB models based on the culture of endothelial cells and astrocytes and/or pericytes, including MDCK-MDR1 cell model, BBB-PAMPA model and microvascular endothelial cell/astrocytic/pericyte model. With the established BBB model, Creative Bioarray can provide basic research on BBB and experimental tests on the interaction between BBB and potential drug candidates.

Assessing the permeability of the BBB is essential for assessing the severity of neurological diseases and developing drugs for the treatment of neurological diseases. At present, Creative Bioarray has established a simple, reliable and efficient in vivo detection method, which has been successfully applied to a variety of genetic and experimental mouse models.

“Creative Bioarray provides in vivo drug metabolism and pharmacokinetics (DMPK) services to support your drug development research on the in vivo absorption, distribution, metabolism and excretion of candidate drugs. Our in vivo DMPK service covers various animal studies of multiple species.” said Hannah Cole, the marketing director of Creative Bioarray, she also said, “We have extensive experience in designing, executing and interpreting DMPK research results for multiple species. The research design and the selection of appropriate models are usually tailored to the goals of each project. All research can be conducted by well-trained and experienced scientists under strict guidance.”

About Creative Bioarray
Founded in 2005, Creative Bioarray is dedicated to offering customers with innovative biotechnology products and services for research use to greatly enhance and drive innovation and standards in science. As a well-recognized industry leader with more than 10 years of experience and in-house experts supported, Creative Bioarray has already countenanced research all around the world.

Contact Info:
Name: Hannah Cole
Email: Send Email
Organization: Creative Bioarray
Address: Shirley, NY 11967, USA
Phone: 1 631 386 8241
Website: https://www.creative-bioarray.com/

Source URL: https://marketersmedia.com/creative-bioarray-established-in-vitro-and-in-vivo-blood-brain-barrier-assay-to-develop-drugs-for-neurological-diseases/89027035

Source: MarketersMedia

Release ID: 89027035